ARTICLE | Product Development

Supply constraints, logistic hurdles to limit mAb impacts on COVID-19

October 9, 2020 10:47 PM UTC

The speed of the development of COVID-19 mAbs highlights the strengths and weaknesses of the U.S. approach to pandemic countermeasures.

On one hand, mAbs have been created and tested at record-breaking speeds, in part because of technology investments made a decade ago by the Defense Research Advanced Projects Agency (DARPA). ...